The CHARIOT PRO substudy investigated brain amyloid as a biomarker of cognitive impairment due to Alzheimer's disease. Image The CHARIOT PRO study was a commercial study sponsored by Janssen Research. It recruited 500 healthy people aged 60-85 in Edinburgh and London. The main purpose was to assess if early amyloid build up in the brain was a sign of future cognitive impairment (e.g. memory or attention loss). By testing this assumption in healthy individuals the researchers would more better understand the link between amyloid and cognitive impairment, and the timeline of the disease. Currently Recruiting: No This article was published on 2024-08-27
